Table 1.
Dengue vaccine candidates in use or in clinical trials.
| Vaccine Type | Name | Strategy | Clinical Trial Phase |
|---|---|---|---|
| Live Attenuated vaccine | CYD-TDV | Replacing the prM/E gene of the YF17D virus with genes of the DENV1–4 | Evaluation after part of the license |
| TV003/TV005 | Attenuation by truncating 30 nucleotides in the 3′ UTR of DENV1, DENV3, DENV4, and a chimeric DENV2/DENV4 | Phase III | |
| DENVax | Replacing the coding sequences of DENV2 PDK-53 attenuated vaccine with that of DENV1, DENV3, and DENV4 | Phase III | |
| Inactivated virus | PIV | Purified formalin-inactivated virus and adjuvants | Phase I |
| Subunit vaccine | V180 | A recombinant truncated protein containing DEN-80E | Phase I |
| DNA vaccine | D1ME100 | Recombinant plasmid vector encoding prM/E | Phase I |
| TVDV | Recombinant plasmid vector encoding prM/E proteins of DENV1–4 | Phase I | |
| Heterologous prime/boost | TLAV Prime/PIV boost and reverse order | Initial immune-boost strategy | Phase I |
CYD-TDV: the live attenuated chimeric yellow fever 17D virus-tetravalent dengue vaccine; DENVax: the live attenuated tetravalent dengue vaccine; PIV: the purified formalin-inactivated virus vaccine; TVDV: the tetravalent DNA vaccine; TLAV: the tetra-live attenuated virus vaccine.